News

The milestone payment will also be used to start a Phase 1 clinical trial of a HuCAL-derived, fully human antibody to treat inflammatory diseases. MorphoSys chief scientific officer

Cravit IV, administered once daily, is classified as a respiratory quinolone suited to treat respiratory tract infections. Daiichi said that 100mg Cravit tablets were approved in Japan for

The company expects to initiate a Phase 1/2 clinical trial to investigate the safety and efficacy of the drug, in 2011. ISV-101 combines a low dose of the

Amarin has two final-stage human tests of its advanced experimental cholesterol drug AMR101. Bloomberg.com has quoted San Francisco-based Wedbush Securities analyst Duane Nash as saying that the cholesterol

HGS is set to start selling Benlysta along with its partner, London-based GlaxoSmithKline, if the USFDA clears the medicine by 10 March, reported Bloomberg.com. Benlysta prevents the production

SciClone Pharma will recruit around 160 patients who are receiving standard chemoradiation therapy for treatment head and neck cancers. In the trial, the company expects to evaluate three

The results showed improvement in the primary end point, which was defined as a reduction in facial erythema, over an eight hour period in patients with erythematotelangiectatic rosacea

The compounds are Boehringer Ingelheim‘s two oral diabetes agents – linagliptin and BI10773 as well as Lilly‘s two basal insulin analogues – LY2605541 and LY2963016. The agreement also

Merck said that the extended release formulation of Janumet is composed with sitagliptin, Januvia’s (sitagliptin) active component and metformin extended release, which is a treatment for type 2